Barbara Jennifer Gitlitz
University of Southern California · 203 works · 8,515 citations · h-index 45
Top works
- Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
- REEVALUATION OF THE 1997 TNM CLASSIFICATION FOR RENAL CELL CARCINOMA: T1 AND T2 CUTOFF POINT AT 4.5 RATHER THAN 7 CM. BETTER CORRELATES WITH CLINICAL OUTCOME
- Treatment of Metastatic Renal Cell Carcinoma With Nephrectomy, Interleukin-2 and Cytokine-Primed or CD8(+) Selected Tumor Infiltrating Lymphocytes from Primary Tumor
- Renal Cell Carcinoma With Retroperitoneal Lymph Nodes: Role of Lymph Node Dissection
- Renal Cell Carcinoma With Tumor Thrombus Extension: Biology, Role of Nephrectomy and Response to Immunotherapy
- Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
- COLLECTING DUCT RENAL CELL CARCINOMA: CLINICAL STUDY OF A RARE TUMOR
- Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
- Renal cell carcinoma with retroperitoneal lymph nodes
- Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma
- Mathematical Model to Predict Individual Survival for Patients With Renal Cell Carcinoma
- Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
- Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
- Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
- Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
- Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
- EGFR Fusions as Novel Therapeutic Targets in Lung Cancer
- I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib